1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Express Scripts Repatha, Praluent Deals: What It Means

 
• By Donna Young

After all the handwringing about whether payers would cover the newly approved proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors Praluent (alirocumab), marketed by Sanofi SA and Regeneron Pharmaceuticals Inc., and Repatha (evolocumab), from Amgen Inc., Express Scripts Holding Co., the largest pharmacy benefit management (PBM) company in the US, said it has sealed deals for both drugs – declaring it has scored discounts on the medicines, which means neither will be excluded from its formulary.

After all the handwringing about whether payers would cover the newly approved proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors Praluent (alirocumab), marketed by Sanofi SA and Regeneron Pharmaceuticals Inc., and Repatha (evolocumab), from Amgen Inc., Express Scripts Holding Co., the largest pharmacy benefit management (PBM) company in the US, said it has sealed deals for both drugs – declaring it has scored discounts on the medicines, which means neither will be excluded from its formulary.

Express Scripts said its agreements with the PCSK9 inhibitor makers to put Praluent and Repatha on the PBM's "national preferred...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapy Areas

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.